Ovarian Cancer | Specialty

Avelumab Misses Primary Endpoints in Phase III Ovarian Cancer Trial

November 19th 2018

Avelumab (Bavencio) alone or in combination with pegylated liposomal doxorubicin did not induce a statistically significant improvement in overall survival or progression-free survival versus pegylated liposomal doxorubicin alone in patients with platinum-resistant/-refractory ovarian cancer.

Dr. Markman Discusses the Future of Treatment for Ovarian Cancer

November 15th 2018

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care® for Gynecological Cancers, discusses the future of treatment for patients with ovarian cancer.

Novel Targeted Agents Emerging in Ovarian Cancer

November 15th 2018

Diana P. English, MD, discusses the promise for ADCs in the landscape of ovarian cancer treatment and targeting p53 mutations in patients with ovarian cancer.

Pegylated Doxorubicin/Carboplatin Plus Bevacizumab Improves PFS in Recurrent Ovarian Cancer

November 14th 2018

The combination regimen of pegylated liposomal doxorubicin with bevacizumab was found to significantly improve progression-free survival versus carboplatin/gemcitabine in select patients with recurrent ovarian cancer.

Long-Term Maintenance Olaparib Safe and Effective for Patients With Recurrent Ovarian Cancer

November 14th 2018

Long-term maintenance therapy with olaparib (Lynparza) tablets demonstrated a low rate of treatment discontinuation and tolerable safety profile in patients with platinum-sensitive recurrent ovarian cancer.

Dr. Nguyen on Treatment Approaches for Patients With Advanced Ovarian Cancer

November 14th 2018

Trung Nguyen, DO, MBA, clinical assistant professor, Obstetrics and Gynecology, Gynecologic Oncology, Stanford Medicine, discusses treatment approaches for patients with advanced ovarian cancer.

Dr. Dorigo on Immunotherapy in Ovarian Cancer

November 13th 2018

Oliver Dorigo, MD, PhD, associate professor of Obstetrics and Gynecology, Stanford University Medical Center, Stanford Medicine, discusses the use of immunotherapy in the treatment of patients with ovarian cancer.

Lurbinectedin Does Not Improve PFS in Platinum-Resistant Ovarian Cancer

November 12th 2018

Results of the phase III CORAIL trial demonstrated that the marine-derived treatment lurbinectedin did not improve progression-free survival compared with pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer.

FDA Grants Olaparib Priority Review for Frontline Maintenance in Ovarian Cancer

November 12th 2018

The FDA has granted a priority review designation to a supplemental new drug application for olaparib tablets for use as a maintenance therapy in patients with newly-diagnosed, BRCA-positive advanced ovarian cancer who achieved a complete or partial response to standard frontline platinum-based chemotherapy.

Dr. Berek Discusses the Impact of PARP Inhibitors on Ovarian Cancer

November 10th 2018

Jonathan S. Berek, MD, MMS, Laurie Kraus Lacob Professor, Stanford University School of Medicine, director, Stanford Women’s Cancer Center, senior advisor, Stanford Cancer Institute, discusses the impact of PARP inhibitors on the treatment landscape of ovarian cancer.

Real-World Data With Niraparib Show Lower AEs Vs ENGOT-OV6/NOVA Trial in Ovarian Cancer

November 8th 2018

Real-world incidences of nausea, thrombocytopenia, and fatigue were markedly lower in patients with platinum-sensitive, recurrent ovarian cancer receiving a starting 200-mg daily dose of niraparib versus those enrolled on the phase III ENGOT-OV6/NOVA trial.

PFS Improved With Maintenance Rucaparib in Recurrent Ovarian Cancer Irrespective of Prior Chemo

November 7th 2018

In patients with platinum-sensitive recurrent ovarian cancer, the PARP inhibitor rucaparib as maintenance treatment improved progression-free survival versus placebo, despite the number of chemotherapy regimens.

The Importance of Genetic Testing Following a Diagnosis of Ovarian Cancer

November 2nd 2018

Peter Levonian, MS, senior genetic counselor, Stanford Medicine, discusses the importance of genetic testing following a diagnosis of ovarian cancer.

Dr. Karam on Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Ovarian Cancer

October 27th 2018

Amer Karam, MD, associate clinical professor, Gynecologic Oncology, Stanford Hospital, director, Robotic Surgery and Outreach, Division of Gynecologic Oncology, Stanford Medicine, discusses primary debulking surgery versus neoadjuvant chemotherapy in the treatment of patients with ovarian cancer.

Dr. Powell on Tumor Mutational Burden in Ovarian Cancer

October 23rd 2018

Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses tumor mutational burden (TMB) in ovarian cancer.

Olaparib Substantially Improves PFS as Frontline Maintenance in Ovarian Cancer

October 22nd 2018

The PARP inhibitor olaparib significantly improved progression-free survival as frontline maintenance therapy for women with BRCA-positive advanced ovarian cancer, according to findings from the randomized phase III SOLO-1 trial.

Engineered Anti-MAGE-A T-Cells Show Early Promise

October 21st 2018

Genetically engineered T-cells targeting a common tumor antigen appeared safe and demonstrated some evidence of antitumor activity in a first-in-human clinical evaluation.

ESMO 2018: Dr. Verma Sheds Light on Breast Cancer Data

October 21st 2018

ESMO 2018: Dr. Ramalingam Shares Insight on Lung Cancer Studies

October 21st 2018

ESMO 2018: Dr. Abou-Alfa Discusses Updates in GI Cancer

October 21st 2018